MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells

Carcinogenesis

Volumn 33, Issue 3, 2012, Pages 687-693

  Garrido, Cristina ^a,b   Paco, Laura ^b   Romero, Irene ^b   Berruguilla, Enrique ^b   Stefansky, Julia ^c   Collado, Antonia ^b   Algarra, Ignacio ^d   Garrido, Federico ^a,b   Garcia Lora, Angel M ^b  

^a UNIVERSITY OF GRANADA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF JAÉN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A1; HLA A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENICITY; CELL CYCLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENETIC TRANSFECTION; HAPLOTYPE; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; IN VITRO STUDY; IN VIVO STUDY; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 84857929365     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr318     Document Type: Article

References (49)

1. Brodsky, F.M. et al. (1991) The cell biology of antigen processing and presentation. Annu. Rev. Immunol., 9, 707-744.
2. Boon, T. et al. (2006) Human T cell responses against melanoma. Annu. Rev. Immunol., 24, 175-208.
3. Rosenberg, S.A. (1999) A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity, 10, 281-287.
4. Novellino, L. et al. (2005) A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother., 54, 187-207.
5. Seliger, B. et al. (2002) HLA class I antigen abnormalities and immune escape by malignant cells. Semin. Cancer Biol., 12, 3-13.
6. Aptsiauri, N. et al. (2007) MHC class I antigens and immune surveillance in transformed cells. Int. Rev. Cytol., 256, 139-189.
7. Garrido, F. et al. (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today, 18, 89-95.
8. Garrido, F. et al. (2001) MHC antigens and tumor escape from immune surveillance. Adv. Cancer Res., 83, 117-158.
9. Hicklin, D.J. et al. (1998) beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J. Clin. Invest., 101, 2720-2729.
10. Garcia-Lora, A. et al. (2003) MHC class I antigens, immune surveillance, and tumor immune escape. J. Cell. Physiol., 195, 346-355.
11. Mendez, R. et al. (2009) HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank. Cancer Immunol. Immunother., 58, 1507-1515.
12. Chang, C.C. et al. (2005) Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrentmetastases following immunotherapy. J. Immunol., 174, 1462-1471.
13. Garcia-Lora, A. et al. (2003) MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components. Int. J. Cancer, 106, 521-527.
14. Maleno, I. et al. (2002) Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunol. Immunother., 51, 389-396.
15. Dunn, G.P. et al. (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity, 21, 137-148.
16. Dunn, G.P. et al. (2004) The three Es of cancer immunoediting. Annu. Rev. Immunol., 22, 329-360.
17. Garrido, C. et al. (2010) Alterations of HLA class I expression in human melanoma xenografts in immunodeficient mice occur frequently and are associated with higher tumorigenicity. Cancer Immunol. Immunother., 59, 13-26.
18. Talmadge, J.E. et al. (2010) AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res., 70, 5649-5669.
19. Paco, L. et al. (2007) Total loss of HLA class I expression on a melanoma cell line after growth in nude mice in absence of autologous antitumor immune response. Int. J. Cancer, 121, 2023-2030.
20. Coulie, P.G. et al. (1992) Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int. J. Cancer, 50, 289-297.
21. Ahmed, S.A. et al. (1994) A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J. Immunol. Methods, 170, 211-224.
22. Baba, T. et al. (2007) Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/B. Cancer Sci., 98, 1795-1802.
23. So, T. et al. (2005) Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer. Cancer Res., 65, 5945-5952.
24. Sabapathy, K. et al. (2008) Defective MHC class I antigen surface expression promotes cellular survival through elevated ER stress and modulation of p53 function. Cell Death Differ., 15, 1364-1374.
25. Garcia-Lora, A. et al. (2001) Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumor variants. Int. J. Cancer, 91, 109-119.
26. Assa-Kunik, E. et al. (2003) Alterations in the expression of MHC class I glycoproteins by B16BL6 melanoma cells modulate insulin receptorregulated signal transduction and augment [correction of augments] resistance to apoptosis. J. Immunol., 171, 2945-2952.
27. Sekimoto, E. et al. (2007) A single-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment. Cancer Res., 67, 1184-1192.
28. Nagy, Z.A. et al. (2002) Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nat. Med., 8, 801-807.
29. Woodle, E.S. et al. (1997) Anti-human class I MHC antibodies induce apoptosis by a pathway that is distinct from the Fas antigen-mediated pathway. J. Immunol., 158, 2156-2164.
30. Spanoudakis, E. et al. (2009) Regulation of multiple myeloma survival and progression by CD1d. Blood, 113, 2498-2507.
31. Melnikova, V.O. et al. (2010) CREB inhibits AP-2alpha expression to regulate the malignant phenotype of melanoma. PLoS One, 5, e12452.
32. Berger, A.J. et al. (2005) Automated quantitative analysis of activator protein-2alpha subcellular expression inmelanoma tissuemicroarrays correlateswith survival prediction. Cancer Res., 65, 11185-11192.
33. Macleod, K.F. et al. (1995) p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev., 9, 935-944.
34. Nakano, K. et al. (1997) Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J. Biol. Chem., 272, 22199-22206.
35. Wajapeyee, N. et al. (2003) Cell cycle arrest and apoptosis induction by activator protein 2alpha (AP-2alpha) and the role of p53 and p21WAF1/CIP1 in AP-2alpha-mediated growth inhibition. J. Biol. Chem., 278, 52093-52101.
36. Zeng, Y.X. et al. (1997) AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression. Nat. Genet., 15, 78-82.
37. Masuda, N. et al. (2003) Synergistic decline in expressions of p73 and p21 with invasion in esophageal cancers. Cancer Sci., 94, 612-617.
38. Schaefer, J.S. et al. (2010) Transcriptional regulation of p21/CIP1 cell cycle inhibitor by PDEF controls cell proliferation and mammary tumor progression. J. Biol. Chem., 285, 11258-11269.
39. Saleem, M. et al. (2008) Lupeol inhibits growth of highly aggressive human metastatic melanoma cells in vitro and in vivo by inducing apoptosis. Clin. Cancer Res., 14, 2119-2127.
40. Sriuranpong, V. et al. (2004) Global gene expression profile of nasopharyngeal carcinoma by laser capture microdissection and complementary DNA microarrays. Clin. Cancer Res., 10, 4944-4958.
41. Tokumaru, Y. et al. (2004) Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res., 64, 5982-5987.
42. Kitkumthorn, N. et al. (2006) Cyclin A1 promoter hypermethylation in human papillomavirus-associated cervical cancer. BMC Cancer, 6, 55.
43. Wang, Y.V. et al. (2009) Guarding the guardian: Mdmx plays important roles in setting p53 basal activity and determining biological responses in vivo. Cell Cycle, 8, 3443-3444.
44. Kondo, I. et al. (2008) MDM2 mRNA expression in the p53 pathway may predict the potential of invasion and liver metastasis in colorectal cancer. Dis. Colon Rectum, 51, 1395-1402.
45. Saito, H. et al. (2002) The expression of murine double minute 2 is a favorable prognostic marker in esophageal squamous cell carcinoma without p53 protein accumulation. Ann. Surg. Oncol., 9, 450-456.
46. Malumbres, M. et al. (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer, 9, 153-166.
47. Campaner, S. et al. (2010) Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat. Cell Biol., 12 (suppl. 1-14), 54-59.
48. Georgieva, J. et al. (2001) Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions. J. Clin. Pathol., 54, 229-235.
49. Halaban, R. et al. (2000) Deregulated E2F transcriptional activity in autonomously growing melanoma cells. J. Exp. Med., 191, 1005-1016.